CytomX Therapeutics develops Probody⢠therapeutics for the treatment of cancer. Probody therapeutics are fully recombinant masked antibodies that are designed to remain inert in healthy tissue but become activated specifically in the tumor microenvironment. The Probody approach is designed to blunt systemic toxicities associated with antibodies and expand the therapeutic window of these drugs, potentially unlocking new therapeutic targets. The Company is initially focusing this highly innovative platform to discover and develop new immunotherapy and antibody drug conjugate therapies to treat areas of major unmet medical need in oncology. Source
No articles found.
Ansell Limited provides health and safety protection solutions. The Company has op...
Ansell Limited provides health and safety prote...
Sienna Biopharmaceuticals, Inc. is a clinicalâstage biopharmaceutical company fo...
Sienna Biopharmaceuticals, Inc. is a clinicalâ...
Natureâs Sunshine Products (NASDAQ:NATR), a leading natural health and wellness ...
Natureâs Sunshine Products (NASDAQ:NATR), a l...
Akcea Therapeutics is a development and commercialization company focused on helpi...
Akcea Therapeutics is a development and commerc...
Neos Therapeutics develops, manufactures, and commercializes innovative extended-r...
Neos Therapeutics develops, manufactures, and c...
Amphastar Pharmaceuticals, Inc., headquartered in Rancho Cucamonga, California, es...
Amphastar Pharmaceuticals, Inc., headquartered ...
20/20 GeneSystems, Inc. an early stage digital diagnostics company with the core m...
20/20 GeneSystems, Inc. an early stage digital ...
Join the National Investor Network and get the latest information with your interests in mind.